Drug Profile
Research programme: menin-MLL inhibitors - Kura Oncology
Alternative Names: KO 381; KO 382; MI 463; MI 503Latest Information Update: 18 Jan 2023
Price :
$50
*
At a glance
- Originator University of Michigan
- Developer Kura Oncology; University of Michigan
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein-protein interaction inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute biphenotypic leukaemia; Leukaemia
Most Recent Events
- 10 Dec 2022 Pharmacodynamics data from a preclinical trial in Lymphoid leukemia presented at the64th American Society of Hematology Annual Meeting and Exposition 2022 (ASH-Hem-2022)
- 28 Dec 2019 No recent reports of development identified for preclinical development in Acute-biphenotypic-leukaemia in USA (PO)
- 28 Dec 2019 No recent reports of development identified for preclinical development in Leukaemia in USA (PO)